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Abstract: Upon binding with the chemokine CXCL12, the chemokine receptor CXCR4 has been
shown to promote breast cancer progression. This process, however, can be affected by the expression
of the atypical chemokine receptor ACKR3. Given ACKR3’s ability to form heterodimers with
CXCR4, we investigated how dual expression of both receptors differed from their lone expression in
terms of their signalling pathways. We created single and double CXCR4 and/or ACKR3 Chinese
hamster ovary (CHO) cell transfectants. ERK and Akt phosphorylation after CXCL12 stimulation was
assessed and correlated with receptor internalization. Functional consequences in cell migration and
proliferation were determined through wound healing assays and calcium flux. Initial experiments
showed that CXCR4 and ACKR3 were upregulated in primary breast cancer and that CXCR4 and
ACKR3 could form heterodimers in transfected CHO cells. This co-expression modified CXCR4’s Akt
activation after CXCL12’s stimulation but not ERK phosphorylation (p < 0.05). To assess this signalling
disparity, receptor internalization was assessed and it was observed that ACKR3 was recycled to
the surface whilst CXCR4 was degraded (p < 0.01), a process that could be partially inhibited with a
proteasome inhibitor (p < 0.01). Internalization was also assessed with the ACKR3 agonist VUF11207,
which caused both CXCR4 and ACKR3 to be degraded after internalization (p < 0.05 and p < 0.001),
highlighting its potential as a dual targeting drug. Interestingly, we observed that CXCR4 but not
ACKR3, activated calcium flux after CXCL12 stimulation (p < 0.05) and its co-expression could
increase cellular migration (p < 0.01). These findings suggest that both receptors can signal through
ERK and Akt pathways but co-expression can alter their kinetics and internalization pathways.
Keywords: chemokines; metastasis; heterodimerization; CXCR4; ACKR3; CXCR7
1. Introduction
Breast cancer is the most prevalent cancer in the United States despite being predominantly a
female disease, with 246,660 new cases expected to occur in 2016 [1]. Although there has been a decline
in mortality rates thanks to improvements in targeted treatments and prevention, breast cancer is still
expected to be the second most common cause of cancer death due to its metastasis to vital organs [2–4].
Thus, it remains vital to develop new targeted therapies to prevent this spread.
Since their discovery over 30 years ago, numerous chemokines have been identified in relation
to cancer spread. Chemokines, or chemotactic cytokines are small (8–14 kDa) proteins that bind to
G-protein-coupled chemokine receptors (GPCR) in order to induce chemotaxis [5]. Upon binding,
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chemokines can activate multiple signalling pathways and gene expression but it was their role
in promoting leukocyte migration to the site of inflammation that allowed for the finding of the
link between chemokines and cancer metastasis [6]. The discovery that cancer cells overexpress the
chemokine receptor CXCR4 and that its blocking can inhibit metastasis to organs that express its
ligand, the chemokine CXCL12 [7–9], opened new therapeutic avenues for the targeting of metastatic
breast cancer.
Furthermore, it was recently discovered that the atypical chemokine receptor ACKR3 is also
upregulated in many cancers, including breast [10–12]; however, reports are contradictory on whether
ACKR3 expression is pro- or anti-metastatic. Unlike other chemokine receptors, ACKR3 has not been
shown to activate G-proteins, most likely due to a change in the alanine and valine in the DRYLAIV
motif that may affect the potential coupling [13]. This means that upon the binding of its ligands
CXCL11 and CXCL12, ACKR3 does not activate G-proteins and instead it mediates their capture and
degradation via β-arrestin due to its tenfold higher affinity for CXCL12 than CXCR4 [14]. However,
it was recently proposed that β-arrestin can serve as a scaffold to which several kinases can bind and
become activated [15], including ERK [15,16] and Akt [17].
Adding further complexity, ACKR3 can form heterodimers with CXCR4 as efficiently as
homodimers [18–20] but its functional consequences are still contradictory. Indeed, there is compelling
evidence that these complexes can have distinct effects from their corresponding homodimers [21],
possibly through differential recruitment. It has been proposed that the formation of this heterodimer
causes conformational changes that affect the CXCR4/Gαi interaction, which is reflected in an altered
signalling response [20]. This was further explored by Décaillot and colleagues, who suggested that
heterodimerization caused the abrogation of the G-protein in favour of β-arrestin signalling [22].
Heterodimerization, thus, adds a new layer of intricacy to receptor-ligand interactions but also opens
exciting possibilities for a more precise targeting strategy.
The current study was designed to explore how the role of CXCR4/ACKR3 co-expression differs
from their homodimer counterparts in a CHO model. In this study we show that ACKR3 activates
kinases differently to CXCR4 and modulates ERK and Akt activation span when co-expressed.
We demonstrate that co-expression can also alter receptor internalization, in particular when
cross-desensitizing with the ACKR3 agonist VUF11207. We also describe that, although ACKR3
does not directly mediate migration towards CXCL12, it can enhance migration of cells co-expressing
CXCR4 and ACKR3 as compared to CXCR4 alone. However, this mechanism does not seem to be
mediated by calcium flux.
2. Results
2.1. In Vivo CXCR4 and ACKR3 Expression in Breast Cancer Tissue
CXCR4 and ACKR3 expression was assessed in patient samples with invasive ductal carcinoma
(Figure 1, left) and invasive lobular carcinoma (Figure 1, right) using immunohistochemistry.
Expression of both receptors was high, with different staining patterns between cancer types. CXCR4
staining in ductal carcinoma was mainly present in the cytoplasm and cell surface, particularly
around the ducts, whilst in lobular carcinoma staining was mostly cytoplasmic but was also present
in the nucleus of most infiltrating cells. ACKR3 staining followed the same pattern as CXCR4—in
ductal carcinoma ACKR3 was exclusively present in the cytoplasm and although it was also mostly
cytoplasmic in lobular carcinoma, infiltrating cells also presented nuclei staining. Unlike CXCR4,
however, staining was particularly strong in the walls of blood vessels. Positive and negative controls
for ACKR3 staining can be found in Figure S1.
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Figure 1. CXCR4 and ACKR3 staining using IHC in breast cancer tissue. 4 μm sections from human 
breast cancer were stained for CXCR4 (1:40) and ACKR3 (1:100) using immunohistochemistry 
following no pre-treatment or EDTA antigen retrieval pre-treatment, respectively. Briefly, protocol 
from the VECTASTAIN ABC HRP kit was followed, signal was developed using DAB and 
counterstained with haematoxylin. No primary antibody was used as a control. n = 2. 
2.2. Expression of CXCR4 and ACKR3 on Transfected and Breast Cancer Cell Lines 
qPCR and flow cytometric analyses were carried out to assess CXCR4 and ACKR3 expression in 
four breast cancer cell lines, however none expressed both receptors at high levels. Thus, to evaluate 
the roles of these receptors, CXCR4 and/or ACKR3 were stably overexpressed in CHO cells using 
lipid-based transfection and clones with highest expression levels at the cell membrane were 
selected and used in subsequent experiments (Figure 2A). Transient transfectants were used for 
CHO-CXCR4-ACKR3 cells and two different CHO-ACKR3 clones were assessed, however only one 
is shown in this study. Receptor expression of the transfected cells in comparison to breast cancer 
cell lines was evaluated using flow cytometric analyses (Figure 2B), showing that MDA-MB-231, 
MCF-7, SKBR3 and T47D express very low levels of CXCR4. On the other hand, MCF-7 cells 
expressed high levels of ACKR3 to a level comparable to CHO-CXCR4-ACKR3, whilst T47D 
Figure 1. CXCR4 and ACKR3 staining usi st cancer ti sue. 4 µm sections from human
breast cancer were stained for CXCR4 (1:40) and ACKR3 (1:100) using immunohistochemistry following
no pre-treatment or EDTA antigen retrieval pr -treatment, resp ctively. Briefl , p otocol from the
VECTASTAIN ABC HRP kit was followed, signal was developed using DAB and counterstained with
haematoxylin. No primary antibody was used as a control. n = 2.
2.2. Expression of CXCR4 and ACKR3 on Transfecte cer Cell Lines
qPCR and flow cyto etri s ere ca ried out to as ess XCR4 and ACKR3 xpression
in four breast cancer cell lines, however none xpressed both receptors at high lev ls. Thus,
to evaluate the roles of these receptors, CXCR4 and/or ACKR3 wer stably overexpressed in CHO
cells using lipid-based transfection and clones with highest expression levels at the cell membrane
were selected and used in subsequent experiments (Figure 2A). Transient transfectants were used for
CHO-CXCR4-ACKR3 cells and two different CHO-ACKR3 clones were assessed, however only one is
shown in this study. Receptor expression of the transfected cells in comparison to breast cancer cell
lines was evaluated using flow cytometric analyses (Figure 2B), showing that MDA-MB-231, MCF-7,
SKBR3 and T47D express very low levels of CXCR4. On the other hand, MCF-7 cells expressed high
levels of ACKR3 to a level comparable to CHO-CXCR4-ACKR3, whilst T47D expressed moderate
Int. J. Mol. Sci. 2018, 19, 3592 4 of 18
levels and MDA-MB-231 and SKBR3 expressed very low levels. mRNA analysis produced similar
results and confirmed the observed CXCR4 and ACKR3 expression.
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 18 
 
expressed moderate levels and MDA-MB-231 and SKBR3 expressed very low levels. mRNA analysis 
produced similar results and confirmed the observed CXCR4 and ACKR3 expression. 
In order to confirm whether CXCR4 and ACKR3 were forming heterodimers as previously 
reported [18–20], fluorescence resonance energy transfer (FRET) assays were carried out at 
saturating antibody concentrations. FRET analysis showed that CXCR4 and ACKR3 form 
heterodimers with or without the presenc  of CXCL12 (p < 0.05), with o FRET cc rring with 
CXCR4 and MHC I (Figure 2C). 
 
Figure 2. Expression of CXCR4 and/or ACKR3 in transfected CHO cells. CHO cells were transfected 
with pcDNA3.1/Zeo-CXCR4 and/or pcDNA3-ACKR3 using Effectene and selected with antibiotics. 
(A) Histograms showing CXCR4 or ACKR3 expression in the final selected colonies. Cells were 
stained with PE or APC-conjugated antibodies and expression was assessed using flow cytometry 
(Red = Isotype, blue = antibody) on CHO-CXCR4 (left) and CHO-ACKR3 (middle); and red = 
isotype for CXCR4, purple = isotype for ACKR3, green = CXCR4, blue = ACKR3 on 
CHO-CXCR4-ACKR3 (right) cells. (B) Mean fluorescence levels of the transfected CHO cells were 
determined and compared to several breast cancer cell lines to assess CXCR4 (left) and ACKR3 
(right) receptor levels. Data represents the mean ± SEM of three independent experiments and 
statistical significance was calculated using a one way ANOVA (* p < 0.05). (C) Formation of 
heterodimers was assessed using fluorescence resonance energy transfer (FRET) and quantified 
through the FRET ratio from APC (the acceptor fluorochrome). Data represents the mean ± SEM of 
three independent experiments and statistical significance was calculated using a one way ANOVA 
(* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). 
Figure 2. Expression of CXCR4 and/or ACKR3 in transfected CHO cells. C O cells ere transfected
with pcDNA3.1/Zeo-CXCR4 and/or pcDNA3-A 3 using Effectene and selected with antibiotics.
(A) Histograms showing CX R4 or ACKR3 expression in the final selected colo i s. ells were
stained with PE or APC-conjugated antibodies and expres ion was asse i fl cytometry
(Red = Isotype, blue = antibody) n CHO- XCR4 (left) and CHO-ACKR3 (middle); and red = isotype
for CXCR4, purple = isoty e for ACKR3, green = CXC 4, blu = ACKR3 on CHO-CXCR4-ACKR3
(right) cells. (B) Mean fluo escen levels of the transfect d CHO cells w re determined and compared
to several br ast cancer cell lines to assess CXCR4 (left) and ACKR3 (right) receptor levels. Data
represents the mean± SEM of thre ind pendent experiments and statistical significance was calculated
using a one way ANOVA (* p < 0.05). (C) Formation of heterodimers was assessed using fluorescence
resonance energy transfer (FRET) and quantified through the FRET ratio from APC (the acceptor
fluorochrome). Data represents the mean ± SEM of three independent experiments and statistical
significance was calculated using a one way ANOVA (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
In order to confirm whether CXCR4 and ACKR3 were forming heterodimers as previously
reported [18–20], fluorescence resonance energy transfer (FRET) assays were carried out at saturating
antibody concentrations. FRET analysis showed that CXCR4 and ACKR3 form heterodimers with
or without the presence of CXCL12 (p < 0.05), with no FRET occurring with CXCR4 and MHC I
(Figure 2C).
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2.3. CXCR4 and ACKR3 Differentially Activate the Akt and ERK Oncogenic Pathways
Having engineered CHO cell lines overexpressing CXCR4, ACKR3, or both receptors,
we compared their ability to activate ERK and Akt at different time points through Western
Blot and cell-based ELISA. Since the ERK pathway is involved in migration [23,24] and Akt in
proliferation [25,26], we assessed their phosphorylation after CXCL12 stimulation.
CHO-CXCR4 cells presented early p-ERK activation that could be seen at 5 and 15 min but
that had disappeared at 2 h and a similar pattern could be seen for p-Akt (Figure 3A). Conversely,
a continuous activation for both p-ERK and p-Akt could be observed for up to 2 h in CHO-ACKR3
cells (Figure 3B). Interestingly, similarly to CHO-CXCR4, CHO-CXCR4-ACKR3 cells presented an
intense ERK phosphorylation at 5 min that had disappeared at 2 h in both western blot and cell-based
ELISA; but displayed constant p-Akt activation throughout two hours mirroring CHO-ACKR3 cells’
phosphorylation (Figure 3C).
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120 min. (Top) Cells were lysed and immunoblots probed with p-ERK or p-Akt, stripped and 
re-probed for pan-ERK or pan-AKT and GAPDH as a loading control. Images are representative of 
three independent experiments. (Bottom) Cells were fixed with methanol and cell-based ELISA was 
performed as per protocol using p-ERK and total-ERK antibodies with fluorescence intensity 
readings at 600 and 450 nm. Data represents the mean ± SEM of three independent experiments and 
statistical significance was calculated using a one way ANOVA (* p < 0.05, ** p < 0.01). 
2.4. ACKR3 Expression Can Alter CXCR4’s Internalization Pathway 
To investigate whether this difference in signalling was due to receptor internalization, cells 
were stimulated with CXCL12 before replacing the media and monitoring receptor levels using flow 
cytometry. An 80% reduction of CXCR4 levels could be observed after 30 min incubation with 10 nM 
CXCL12 in CHO-CXCR4 cells and when replaced with fresh media no recycling of the receptor 
could be seen after 2 h (Figure 4A)—the same pattern was observed in MDA-CXCR4 cells which 
were used as a physiological control (Figure 4C). Similarly, in CHO-ACKR3 a 50% receptor 
reduction could be seen after a 15-min incubation with 10 nM CXCL12 but when media was replaced 
ACKR3 expression was recovered after 60–90 min, with receptor levels increasing over the initial 
Figure 3. Western blot and cell-based ELISA show that CXCL12 treatment of transfected CHO cells
differentially the ERK and AKT pathways. Serum sta ved (A) CHO-CXCR4, (B) CHO-ACKR3
and (C) CHO-CX R4-ACKR3 cells were stimulated with 10 nM CXCL12 for 5, 5 and 120 min.
(Top) Cells were ly ed and immunoblots probed with p-ERK or p-Akt, strip ed and re-probed for
pan-ERK or pan-AKT and GAPDH as a loading control. Images are representative of thre independent
experiments. (Bottom) Cells were fixed with methanol and cell-based ELISA was performed as per
p otocol using p-ERK and total-ERK antibodies with fluorescence int nsity readings at 600 and 450 nm.
Data represents the mean ± SEM of three independent experiments and statistical significance was
calcul ted using a one way ANOVA (* p < 0.05, ** p < 0.01).
2.4. ACKR3 Expression Can Alter CXCR4’s Internalization Pathway
To investigate whether this difference in signalling was due to receptor internalization, cells
were stimulated with CXCL12 before replacing the media and monitoring receptor levels using flow
cytometry. An 80% reduction of CXCR4 levels could be observed after 30 min incubation with 10 nM
CXCL12 in CHO-CXCR4 cells and when replaced with fresh media no recycling of the receptor could
be seen after 2 h (Figure 4A)—the same pattern was observed in MDA-CXCR4 cells which were used
as a physiological control (Figure 4C). Similarly, in CHO-ACKR3 a 50% receptor reduction could be
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seen after a 15-min incubation with 10 nM CXCL12 but when media was replaced ACKR3 expression
was recovered after 60–90 min, with receptor levels increasing over the initial ones (Figure 4B) and
correlating with the longer kinases’ activation. This phenomenon was also observed in MCF-7 but not in
MDA-ACKR3 cells (Figure 4D), where ACKR3 just returned to original levels. In CHO-CXCR4-ACKR3,
CXCR4 levels also remained at around 50% for up to two hours; conversely ACKR3 levels recycled
back to the surface, although they did not reach the initial level after 2 h (Figure 4E). A representative
histogram for the recycling after CXCL12 stimulation can be found in Figure S2.
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To confirm that CXCR4 was being degraded, cells were pre-treated with 10 μM of the 
proteasome inhibitor lactacystin for 1 h. Lactacystin prevented the degradation of CXCR4 in 
CHO-CXCR4 cells after CXCL12 stimulation, with receptor levels returning to initial levels 2 h after 
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To confirm that CXCR4 was being degraded, cells were pre-treated with 10 µM of the proteasome
inhibitor lactacystin for 1 h. Lactacystin prevented the degradation of CXCR4 in CHO-CXCR4 cells
after CXCL12 stimulation, with receptor levels returning to initial levels 2 h after CXCL12 removal
(Figure 5A). Pre-treatment with lactacystin had no effect in ACKR3 recycling in CHO-ACKR3 cells,
confirming that ACKR3 was not degraded after internalization (Figure 5B). Furthermore, a similar
pattern could be observed in CHO-CXCR4-ACKR3 cells, with CXCR4 expression returning to higher
levels when pre-treated with lactacystin but having no effect in ACKR3 recycling (Figure 5C).
A representative histogram for the recycling with and without lactacystin can be found in Figure S3.
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effect in CXCR4 expression was seen in CHO-CXCR4 cells, confirming the specificity of the 
compound (Figure 6A). Similarly, to what was observed with CXCL12, ACKR3 expression in 
CHO-ACKR3 was recovered after the wash; however, it did not increase further than the original 
levels (Figure 6B)—the same trend was observed in MCF-7 cells. In CHO-CXCR4-ACKR3, CXCR4 
levels decreased around 30%, whilst a 40–50% receptor reduction could be seen for ACKR3 (Figure 
6C). Unlike with CXCL12, ACKR3 did not recycle back to the surface after VUF11207 stimulation. 
In order to assess whether the increase in ACKR3 levels after CXC12 but not 
VUF11207-mediated recycling came from internal ACKR3 stored in vesicles or an increment in 
ACKR3 transcription, the receptor’s RNA levels were evaluated using qPCR. A significant increase 
in ACKR3 RNA expression could be observed at 60–90 min in the CXCL12-stimulated cells, whilst 
expression levels remained constant when cells had been treated with VUF11207 (Figure 6D). These 
Figure 5. Preventing receptor degradation after CXCL12 sti ulation using lactacystin, a proteaso e
inhibitor. ( ) - X R4, (B) - R3 and ( ) - X R4- R3 cells ere pre-treated
for 1 h ith 10 µ lactacystin (a proteoso e inhibitor) before incubating ith 10–50 n L12 for
15–30 min. Cells were then washed and incubated with chemokine-free media for up to 2 h before being
labelled and analysed using a flow cytometer. Data represents the mea ± SEM of three independent
exp riments and statistical significance was calculat d using a one way ANOVA (ns: not significa t,
* p < 0.05, ** p < 0.01, *** p < 0.001).
2.5. ACKR3 Agonist VUF11207 Functions Differently to CXCL12 and Can Cross-Desensitize CXCR4
After sti ulation with 1 n VUF11207 for 30 min, media containing the ligand was replaced
by fresh complete media and receptor levels were monitored using flow cyto etry. No significant
effect in CXCR4 expression was seen in CHO-CXCR4 cells, confirming the specificity of the compound
(Figure 6A). Similarly, to what was observed with CXCL12, ACKR3 expression in CHO-ACKR3 was
recovered after the wash; however, it did not increase further than the original levels (Figure 6B)—the
same trend was observed in MCF-7 cells. In CHO-CXCR4-ACKR3, CXCR4 levels decreased around
30%, whilst a 40–50% receptor reduction could be seen for ACKR3 (Figure 6C). Unlike with CXCL12,
ACKR3 did not recycle back to the surface after VUF11207 stimulation.
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Figure 6. CXCR4 and ACKR3 follow different internalization pathways after VUF11207 stimulation.
(A) CHO-CXCR4, (B) CHO-ACKR3 and (C) CHO-CXCR4-ACKR3 cells were stimulated with 1 nM
VUF11207 for 30 min and then washed and incubated with agonist-free media for up to 2 h to assess
receptor recycling. Cells were then labelled and receptor expression was measured using flow cytometry.
Data represents the mean ± SEM of three independent experiments and statistical significance was
calculated using a one way ANOVA (ns: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001). (D) CXCL12
and VUF11207 have a different effect in ACKR3 transcription. CHO-ACKR3 cells were stimulated
with 1 nM VUF11207 or 10 nM CXCL12 and recycling was assessed as described above. RNA was
then extracted at each time point a d ACKR3 expression was ass ssed using qPCR and normalized to
GAPDH. Data represents the mean± SEM of three independent experiments and statistical significance
was calculated using a one-way ANOVA (* p < 0.05, *** p < 0.001).
In order t assess w ther the increase in ACKR3 levels after CXC12 but not VUF11207-mediated
recycling came from internal ACKR3 stored in vesicles or an increment in ACKR3 transcription, the
receptor’s RNA levels were evaluated using qPCR. A significant increase in ACKR3 RNA expression
could be observed at 60–90 min in the CXCL12-stimulated cells, whilst expression levels remained
constant when cells had been treated with VUF11207 (Figure 6D). These results seem to suggest an
upregulation triggered by the removal of CXCL12, with mRNA increase correlating with increased
protein expression shortly thereafter. A representative histogram for the recycling after VUF11207
stimulation can be found in Figure S4.
2.6. ACKR3 Increases In Vitro Migration to CXCL12 in the Presence of CXCR4
To evaluate the roles of CXCR4 and ACKR3 in CXCL12-induced migration in vitro, a scratch
assay was performed (Figure 7A). Wound-healing assays revealed that CXCL12 treatment significantly
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increased cell front velocity in CHO-CXCR4 (4.229 µm/h) and CHO-CXCR4-ACKR3 (4.766 µm/h) in
comparison to treated WT (2.565 µm/h), although to a lesser extent in the former. Addition of CXCL12
had no significant effect in CHO WT cells or CHO-ACKR3 cells, however wound speed closure was
significantly decreased in CHO-ACKR3 cells in comparison to CHO-CXCR4-ACKR3 cells (Figure 7B).
Proliferation assays were carried both in presence and absence of CXCL12 (10 nM). At 24, 48 & 72 h
there was no significant change in cell proliferation between the wild type and transfectants (Figure S5).
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Figure 7. CXCR4 but not ACKR3, has an effect in wound healing after CXCL12 stimulation. CHO-WT,
CHO-CXCR4, CHO-ACKR3 and CHO-CXCR4-ACKR3 cells were seeded into Ibidi inserts to create a
“wound” 24 h later. Wells were then filled with serum-reduced media with or without 10 nM CXCL12
and wound closure was monitored for 48 h using the Nikon Biostation. (A) Example of images captured
during a wound healing assay, magnification 4× (B) Cell front velocity was calculated from the wound
area. Data represents the mean± SEM of nine independent experiments and statistical significance was
calculated using a two-way ANOVA with Bonferroni post-tests (* p < 0.05, ** p < 0.01). (C) CXCR4- but
not ACKR3-expressing cells show calcium flux in response to CXCL12. Indo-1AM stained cells were
stimulated with 10 nM CXCL12 followed by 4 µM ionomycin as a positive control and intracellular
calcium flux was assessed. A representative plot showing calcium release in CHO-CXCR4 cells can
be seen. (D) Ratio between free Indo-1 AM at 510 nm and calcium-bound Indo-1AM at 420 nm was
calculated and concentration of calcium released was determined. Data is representative of three
independent experiments and statistical significance was calculated using a one-way ANOVA (ns: not
significant, * p < 0.05).
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2.7. Diminished Calcium Flux Induction in ACKR3 Expressing Cell Line
Since the discovery of calcium flux’s role in neutrophil’s migration [27], its role in many
GPCR-mediated chemotaxis, including CXCR4, has been described [28]. We thus aimed to investigate
whether the observed increases in cell front velocity were due to an increased migration or proliferation.
We observed that both CHO-CXCR4 and CHO-CXCR4-ACKR3 cells successfully transduced
intracellular calcium signals in response to CXCL12 (Figure 7C), with no statistically significant
difference between the two. Calcium flux was however significantly reduced in CHO-ACKR3 cells
compared to the CHO-CXCR4-ACKR3 cells (Figure 7D).
3. Discussion
Chemokines have been reported to regulate not only cancer cell migration and metastasis but
also to stimulate tumour growth and invasion [6,11,29,30]. Since the discovery of ACKR3 as a
CXCL12-binding chemokine receptor in addition to CXCR4 [31], its role in several cancers has been
explored but its effects are still the source of many conflicting reports. For instance, ACKR3 has been
reported to increase cell survival and adhesion [30]; yet studies suggests it both mediates [31,32] and
does not affect chemotaxis [33] and its effects in conjunction with CXCR4 are even less clear [22,34,35].
Thus, a better understanding of the role of ACKR3, in particular in co-expression with CXCR4,
is needed in order to further target these receptors. We separately observed that both ACKR3 and
CXCR4 are overexpressed in breast cancer tumours of two patients with invasive ductal or lobular
carcinoma, an increase also observed elsewhere [36,37]. However none of our breast cancer cell lines
reflected this dual expression. Thus, CHO cells expressing one or both receptors were created and the
presence of CXCR4/ACKR3 heterodimers was confirmed using FRET, a phenomena that has been
previously described in literature [18,20,22].
After CXCL12 stimulation, we observed a transient p-ERK and p-AKT peak activation at 5
and 15 min in CHO-CXCR4 cells; conversely, p-ERK and p-AKT activation remained constant for
up to 2 h in CHO-ACKR3 cells. These results suggest that ACKR3 expression and co-expression
with CXCR4 can regulate CXCL12-driven phosphorylation of Akt but not ERK. This correlates
with previous literature that suggests that ACKR3-mediated activation of these kinases is different
from the canonical G-protein pathway in many ways. For instance, it has been reported that whilst
G-protein-dependent ERK activation is quick and transient [38], β-arrestin-mediated activation is
slower but more sustained [39,40]. Indeed, other studies also report that ACKR3 can activate both
the ERK and Akt pathways through β-arrestin [41–43]. However kinetic reports vary, indicating that
pathways may be activated differentially in time depending on the cell line. For instance, one study
reports the complete opposite effect, with sustained ERK and transient Akt activation [44], whilst
another reports a transient activation of both kinases [32], in partial agreement with our findings; and a
third reports a sustained Akt activation in accordance with our observations [17]. Interestingly, p-ERK
activation in CHO-CXCR4-ACKR3 showed a transient but intense peak at 5 min that disappeared with
time, whilst Akt showed a sustained activation. This ERK pattern was also observed elsewhere [44–46]
but sustained ERK activation has also been reported [22,47,48]. Once again, this is most likely due
to the extreme variability in signalling pathways between cell lines, even within the same disease.
Indeed, Heinrich, Lee [49] reported different activation patterns in two pancreatic cell lines which
co-expressed ACKR3 and CXCR4.
We were interested to know whether these differences in ERK and Akt activation times
could be correlated with the internalization of the receptor and whether it was then degraded or
recycled back to the surface. Indeed, receptor internalization in transfected CHO cells has been
described previously [31,50–52]. We observed that after CXCL12 stimulation, CXCR4 expression in
CHO-CXCR4 and MDA-CXCR4 cells diminished and did not recover for up to 2 h, whilst ACKR3
levels in CHO-ACKR3 and MDA-ACKR3 had gone back to normal after 1 h. This is in accordance
with other studies reporting that ACKR3 gets recycled after promoting CXCL12 degradation [14].
A similar pattern was seen in CHO-CXCR4-ACKR3 cells, albeit ACKR3 recovery levels were lower.
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This is in accordance to Uto-Konomi, McKibben [35], who reported that when ACKR3 and CXCR4
are co-expressed, CXCL12 stimulation induces degradation of CXCR4 but recycling of ACKR3.
Co-internalization of both CXCR4 and ACKR3 was also reported in MCF-7 cells, although further
degradation or recycling was not studied [45]. We also wanted to confirm that CXCR4 was being
degraded through the proteasome pathway and indeed we observed CXCR4 recycling when cells were
pre-treated with the proteasome inhibitor lactacystin. This is in accordance with other studies, which
demonstrated that lactacystin could significantly increase CXCR4 levels [53,54].
Although numerous CXCR4 antagonists have been evaluated as therapeutic agents [55,56],
ACKR3 therapies may provide a new anticancer avenue [57]. Indeed, ACKR3 antagonists have
shown interesting results in inhibiting trans-endothelial migration [58] and ACKR3 agonists have also
shown promise [35], proving that ACKR3 is a potential therapeutic target. Furthermore, desensitization
through agonists has been shown to be a therapeutic avenue in anti-inflammatory diseases [59] and
due to the formation of heterodimers, CXCR4 and ACKR3 are key candidates for cross-desensitization.
In our study, it was observed that VUF11207 caused ACKR3 recycling in CHO-ACKR3 cells, albeit at
lesser levels than when stimulated by CXCL12. qPCR results suggest that this difference in ACKR3
recovery levels could be partially explained by CXCL12-mediated induction of ACKR3 synthesis and
not just by internal ACKR3 reserves [60]. Interestingly, VUF11207 stimulation of CHO-CXCR4-ACKR3
caused a reduction of both CXCR4 and ACKR3 and abrogated ACKR3 recycling, indicating that a
different mechanism may be taking place after receptor activation with VUF11207. One reason for
this difference could be that VUF11207 binds in a different pocket than CXCL12, causing changes in
the recycling of the receptor [61]. Second, VUF11207 could be recycled back to the surface with the
receptor, causing a continuous internalization. Indeed, after internalization CXCL12 is dissociated from
the receptor in the late endosomes and degraded but some ligands remain bound [62], for instance
AMD3100 has been reported to be bound to CXCR4 for over 24 h [63]. Third, due to their different
molecular weight there may be changes in receptor dimerization after ligand binding—indeed, CXCL12
is approximately 8 kDa, whilst VUF11207 only has a molecular weight of 584 Da, which could result in
different sterically hindrances that may cause an altered conformation [18].
ACKR3’s ability to mediate or enhance chemotaxis has been mixed, with some studies suggesting
it plays a role in migration [22,31,32,34] and others reporting it does not [33,35,43,64,65]. Our findings
are consistent with the latter, suggesting that ACKR3 alone does not mediate CXCL12-mediated
chemotaxis but when co-expressed with CXCR4 it increases cell front velocity in the presence of
CXCL12, similarly to that observed by Inaguma et al. [48]. These differences are most likely due
to different expression levels of ACKR3, with higher levels scavenging all CXCL12 and impairing
migration, whilst lower levels create a steep CXCL12 gradient that favours it. In contrast, CXCL12
significantly increased the wound healing speed in CHO-CXCR4 cells, a phenomena that has been
reported in other wound healing assays [66,67].
Calcium flux has been widely reported to mediate cell migration through actin polarization,
pseudopodia formation and adhesion to fibronectin [68] and thus we aimed to assess whether the
differences observed in cell front velocity were due to an increased intracellular calcium release. Indeed,
we observed CXCL12-mediated calcium flux induction in CHO-CXCR4 cells, a phenomena that has
been described previously [30,69] and in correlation with previous studies [19,30,33] calcium flux was
significantly impaired in CHO-ACKR3 cells. This further supports that ACKR3 does not interact
with G-proteins due to having a DRYLSIT, instead of DRYLAIV, motif [70]. Interestingly, calcium
flux in CHO-CXCR4-ACKR3 cells was not significantly different to CHO-CXCR4 or CHO-ACKR3,
although its cell front velocity was significantly increased compared to CHO-ACKR3. This suggests
that the difference observed in cell front velocity could be due to increased proliferation. However, we
did not observe any significant change in proliferation both in the presence and absence of CXCL12.
Other studies in endometrial cancer have shown that inhibition of these two receptors can reduce
proliferation in cell lines [71] and both can be involved in proliferation in thyroid cancer, although
their role depends on the cell line used [49]. Exposure to CXCL12 in prostate epithelial cell lines which
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express both receptors also causes an increased proliferative rate and blocking of CXCR4 or both
receptors blocks CXCL12’s effect [72]. Interestingly, signalling through the Akt but not ERK pathway
has been shown to induce proliferation in mammary epithelial cells [73], which correlates with the
phosphorylation we observe in CHO-CXCR4-ACKR3 cells. Once again, the role of these kinases is
likely cell line dependent [72].
In summary, our study highlights that CXCR4 and ACKR3 co-expression creates a distinct
signalling entity with unique properties. Despite its over-expression in many cancer cell lines [30],
the data presented suggests that ACKR3 does not have a role in chemotaxis but its presence can
increase cell front velocity if co-expressed with CXCR4. Furthermore, we have seen that ACKR3 can
induce ERK and Akt phosphorylation in a different kinetic and spatial sequence to CXCR4 and alter
receptor internalization and thus may still be involved in other pathways such as NF-κB-mediated
survival, tumour growth and angiogenesis. Furthermore, we have also shown that the ACKR3 agonist
VUF11207 differentially desensitizes ACKR3, which could contribute to a new line of therapy.
4. Materials and Methods
4.1. Immunohistochemistry
Ethical approval for the use of paraffin-embedded samples from breast cancer tumours was
submitted for proportionate review to the Research Ethics Committee (NHS Health Research Authority)
and approved on the 14 March 2016 under the REC reference 16/YH/0117 (IRAS project ID 188839) by
the Proportionate Review Sub-committee of the Yorkshire & The Humber—Leeds East. For the use
of samples isolated prior to the Human Tissue Authority (HTA), approval had already been granted
under the REC reference 06/Q0906/12. Informed consent was obtained from all subjects.
Immunohistochemistry of 4 µM paraffin-embedded cancer sections was carried out using
the immunoperoxidase-based Vectastain ABC kit (Vector labs, Burlingame, CA, USA) as per the
manufacturer’s instructions. Antigen retrieval was carried out using citrate buffer (pH 6) for 2 min
and unspecific binding was blocked before anti-CXCR4 (1:40, MAB172, R&D systems, Minneapolis,
MN, USA) or anti-ACKR3 (1:150, ab38089, Abcam, Cambridge, UK) antibodies were incubated with
the sections for 2 h at room temperature. For anti-ACKR3 have used placenta as a positive control and
non-immune rabbit serum as a negative control (Figure S4). Secondary and tertiary antibodies were
added for 30 min before dispensing DAB on top of the samples (DAB Peroxidase (HRP) Substrate Kit,
Vector labs, Burlingame, CA, USA) and counterstaining with haematoxylin.
4.2. Cell Culture
Wild-type CHO cells (CHO WT) (ATCC) were cultured in Ham’s F12 medium (Thermo Fisher
Scientific, Waltham, MA USA) supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL
streptomycin and 0.146 g/L L-glutamine in a humidified incubator with 5% CO2 at 37 ◦C.
MDA-MB-231-CXCR4 and MDA-MB-231-ACKR3 were a gift from Kathryn E Luker, Ph.D (Centre for
Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, MI, USA) and were
grown as previously described [14].
4.3. Construction of Stable and Transient Transfectants
The mammalian cell expression vector pcDNA3.1Zeo (Thermo Fisher Scientific, Waltham, MA,
USA) containing CXCR4 was transfected into CHO WT cells as described previously [74]. ACKR3
cDNA from the pCMV-XL5/ACKR3 vector (OriGene, Rockville, MD, USA) was cut and cloned into a
pcDNA3 vector and transfected into CHO WT and CHO-CXCR4 cells using Effectene (Qiagen, Hilden,
Germany). Stable CHO-ACKR3 cell lines were obtained by growing transfected cells at low density for
24 h followed by the addition of 800 µg/mL G418 for selection over 3 weeks. Clones were picked and
expanded before ACKR3 expression assessment and a single cell dilution of the highest expressing
Int. J. Mol. Sci. 2018, 19, 3592 13 of 18
colonies was carried out. Transient CHO-CXCR4-ACKR3 transfected cells were created using Effectene
(Qiagen, Hilden, Germany) 24 h prior to the assay.
4.4. Cell Surface Expression of Chemokine Receptors
The CXCR4-Phycoerythrin (PE) antibody (Clone 12G5, R&D systems, Minneapolis, MN, USA) and
ACKR3-Allophycocyanin (APC) antibody (Clone 11G8, R&D systems, Minneapolis, MN, USA) used in
this study were all fully optimized before the collection of quantitative data. Briefly, 2 × 105 cells were
incubated with the corresponding antibody in 50 µL FACS buffer (2% BSA/PBS) for 30 min or 90 min,
respectively, at 4 ◦C before washing and resuspending cells in 100 µL FACS buffer. Receptor expression
was recorded using a FACS Canto II (BD Biosciences, Franklin Lakes, NJ, USA) and analysed using
FlowJo 7 (FlowJo, Ashland, OR, USA).
To assess receptor internalization, cells were serum starved for one hour before being stimulated
with 10 nM CXCL12 (for CHO-CXCR4, CHO-ACKR3, MDA-CXCR4 and MDA-ACKR3) or 50 nM
CXCL12 (for CHO-CXCR4-ACKR3) for 15 min (CHO-ACKR3) or 30 min (CHO-CXCR4, MDA-CXCR4,
MDA-ACKR3 and CHO-CXCR4-ACKR3). Chemokine was then washed with PBS and cells were
incubated with fresh media at 37 ◦C for various time periods before harvesting. If necessary, cells were
pre-incubated with 10 µM lactacystin for 1 h. For VUF11207, all cells were incubated 1 nM VUF11207
for 30 min. Cells were then labelled and analysed by FACS as described above.
4.5. FRET
FRET was assessed by flow cytometry with excitation of CXCR4-PE at 488 nm and measurement
of emission from ACKR3-APC at 675 nm [75]. To demonstrate that FRET was non-random, both
antibodies were titrated to a saturating concentration and MHC I-APC (2G5, Novus Biologicals,
Centennial, CO, USA) was used as a negative control. Energy transfer efficiencies calculated as the
ratio between APC’s mean fluorescence intensity (MFI) on its own and with CXCR4.
4.6. Western Blot
After serum starvation for one hour, cells were stimulated with 10 nM CXCL12 for various time
periods before being lysed with 50 µL of CelLytic M Cell Lysis Reagent (Sigma-Aldrich, St. Louis,
MO, USA) supplemented with cOmplete™ Mini Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis,
MO, USA) and PhosSTOP™ Phosphatase Inhibitor Cocktail (Sigma-Aldrich, St. Louis, MO, USA).
Cell lysates were run in a 10% SDS-PAGE gel electrophoresis and then transferred onto nitrocellulose
membranes. Membrane was blocked with 5% BSA/PBS for one hour before being incubated with
p-ERK (1:1000, Cell Signalling, Danvers, MA, USA) or p-Akt (1:1000, Cell Signalling, Danvers,
MA, USA) antibodies overnight and detected using a horseradish peroxidase-linked secondary
antibody (1:4000, Santa Cruz Biotechnology, Dallas, TX, USA). Immunoblots were developed using
SuperSignal™ West Pico Chemiluminescent Substrate (ThermoFisher, Waltham, MA, USA) according
to manufacturer’s instructions. Re-blotting was performed to quantify the total amount of ERK (1:2000,
Cell Signalling, Danvers, MA, USA), Akt (1:2000, Cell Signalling, Danvers, MA, USA) and GAPDH
(1:2000, Abcam, Cambridge, UK) for normalization.
4.7. Cell-Based ELISA
Relative ERK phosphorylation of transfected CHO cells was determined using a cell-based ELISA
(R&D systems, Minneapolis, MN, USA) as per manufacturer’s instructions. Briefly, cells were grown
in 96-well plates and stimulated with 10 nM CXCL12 for various time periods before being fixed.
Endogenous peroxidase was quenched and cells were blocked and incubated with p-ERK and total
ERK antibodies overnight. The next day, cells were incubated with secondary antibodies conjugated to
either HRP or alkaline phosphatase (AP) and fluorescence was measured at two different wavelengths.
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4.8. qPCR
mRNA expression of ACKR3 after treatment with CXCL12 or VUF11207 was assessed using the
StepOnePlusTM PCR machine (Applied Biosystems Waltham, MA, USA). Cells were treated with either
ligand as described above and lysed using the RNeasy Mini Kit (Qiagen, Hilden, Germany). 1 µg RNA
was used for reverse transcription with the Tetro cDNA synthesis kit (Bioline, London, UK) and cDNA
was used for qPCR with the SensiFast Probe Hi-ROX Mix (Bioline, London, UK) and ACKR3 Taqman
probes (Applied Biosystems Waltham, MA, USA). RNA expression was normalized to GAPDH and
quantified using the 2−∆∆Ct method.
4.9. Wound Healing Assay
In order to assess cell migration through time, a wound healing assay was carried out using 2-well
Ibidi inserts (Ibidi, Martinsried, Germany). Briefly, inserts were placed into a 12-well plate and 70 µL
of 4 × 105 cells/mL were added to each side of the insert and left to grow into a confluent monolayer
under serum starvation conditions. The next day, the insert was removed to create the “scratch” and
serum-reduced media with or without 10 nM CXCL12 was added. Wound closure was then monitored
for 48 h using the NIKON Biostation CT (Nikon, Tokyo, Japan) and analysed using the NIS-Elements
AR software (Nikon, Tokyo, Japan). Cell front velocity was calculated as described in Ibidi’s website
(Available online: https://ibidi.com/img/cms/support/AN/AN21_Wound_Healing_Assay.pdf).
4.10. Calcium Flux
Changes in intracellular Ca2+ concentrations in response to 10 nM CXCL12 and 1 µM of
the calcium ionophore ionomycin (Sigma-Aldrich, St. Louis, MO, USA) were analysed using
calcium-responsive dye fluorescence and flow cytometry. Briefly, 1 × 106 cells were stained with 4 µL
of 1 mg/mL Indo-1 AM in 100 µL supplemented PBS (containing 1 mmol/L CaCl2, 1 mmol/L MgCl2
and 1% FBS) for 30 min at 37 ◦C. Cells were washed and resuspended in 1 mL supplemented PBS and
rested at 37 ◦C for 30 min before analysis. The sample was then analysed using the Fortessa X-20 flow
cytometer BD Biosciences, Franklin Lakes, NJ, USA) with the UV laser for excitation, with 450/50 and
530/30 nm emissions recorded. Baseline readings were taken for 1 min before the addition of 10 nM
CXCL12 for 4 min, followed by 1 µM ionomycin. Finally, the ratio between the two wavelengths was
calculated and plotted against time in order to calculate the peaks of calcium release. To calculate the
intracellular calcium concentration, the following formula was used: [Calcium (nM)] = Kd× ((CXCL12
peak − baseline peak)/(Ionomycin peak − CXCL12 peak)), where Kd is 844 nM, the dissociation
constant of calcium and Indo-1 AM [76,77].
4.11. Statistical Analyses
All results are expressed as means ± SEM of replicate samples. The significance of changes was
assessed by the application of an ANOVA with Bonferroni post-test or two-tailed Student’s t-test.
All data were analysed using Prism 5.0 software (GraphPad Software, La Jolla, CA, USA).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/11/
3592/s1.
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